Cargando…

Ultra‐high performance liquid chromatography coupled to tandem mass spectrometry‐based metabolomics study of diabetic distal symmetric polyneuropathy

AIMS/INTRODUCTION: Distal symmetric polyneuropathy (DSPN) is a common complication of type 2 diabetes mellitus, but the underlining mechanisms have not yet been elucidated. The current study was designed to screen the feature metabolites classified as potential biomarkers, and to provide deeper insi...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jiahui, Chen, Qingguang, Cai, Mengjie, Han, Xu, Lu, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445193/
https://www.ncbi.nlm.nih.gov/pubmed/37347226
http://dx.doi.org/10.1111/jdi.14041
_version_ 1785094124974637056
author Xu, Jiahui
Chen, Qingguang
Cai, Mengjie
Han, Xu
Lu, Hao
author_facet Xu, Jiahui
Chen, Qingguang
Cai, Mengjie
Han, Xu
Lu, Hao
author_sort Xu, Jiahui
collection PubMed
description AIMS/INTRODUCTION: Distal symmetric polyneuropathy (DSPN) is a common complication of type 2 diabetes mellitus, but the underlining mechanisms have not yet been elucidated. The current study was designed to screen the feature metabolites classified as potential biomarkers, and to provide deeper insights into the underlying distinctive metabolic changes during disease progression. MATERIALS AND METHODS: Plasma metabolite profiles were obtained by the ultra‐high liquid chromatography coupled to tandem mass spectrometry method from healthy control participants, patients with type 2 diabetes mellitus and patients with DSPN. Potential biomarkers were selected through comprehensive analysis of statistically significant differences between groups. RESULTS: Overall, 938 metabolites were identified. Among them, 12 metabolites (dimethylarginine, N6‐acetyllysine, N‐acetylhistidine, N,N,N‐trimethyl‐alanylproline betaine, cysteine, 7‐methylguanine, N6‐carbamoylthreonyladenosine, pseudouridine, 5‐methylthioadenosine, N2,N2‐dimethylguanosine, aconitate and C‐glycosyl tryptophan) were identified as the specific biomarkers. The content of 12 metabolites were significantly higher in the DSPN group compared with the other two groups. Additionally, they showed good performance to discriminate the DSPN state. Correlation analyses showed that the levels of 12 metabolites might be more closely related to the glucose metabolic changes, followed by the levels of lipid metabolism. CONCLUSIONS: The finding of the 12 signature metabolites might provide a novel perspective for the pathogenesis of DSPN. Future studies are required to test this observation further.
format Online
Article
Text
id pubmed-10445193
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-104451932023-08-24 Ultra‐high performance liquid chromatography coupled to tandem mass spectrometry‐based metabolomics study of diabetic distal symmetric polyneuropathy Xu, Jiahui Chen, Qingguang Cai, Mengjie Han, Xu Lu, Hao J Diabetes Investig Articles AIMS/INTRODUCTION: Distal symmetric polyneuropathy (DSPN) is a common complication of type 2 diabetes mellitus, but the underlining mechanisms have not yet been elucidated. The current study was designed to screen the feature metabolites classified as potential biomarkers, and to provide deeper insights into the underlying distinctive metabolic changes during disease progression. MATERIALS AND METHODS: Plasma metabolite profiles were obtained by the ultra‐high liquid chromatography coupled to tandem mass spectrometry method from healthy control participants, patients with type 2 diabetes mellitus and patients with DSPN. Potential biomarkers were selected through comprehensive analysis of statistically significant differences between groups. RESULTS: Overall, 938 metabolites were identified. Among them, 12 metabolites (dimethylarginine, N6‐acetyllysine, N‐acetylhistidine, N,N,N‐trimethyl‐alanylproline betaine, cysteine, 7‐methylguanine, N6‐carbamoylthreonyladenosine, pseudouridine, 5‐methylthioadenosine, N2,N2‐dimethylguanosine, aconitate and C‐glycosyl tryptophan) were identified as the specific biomarkers. The content of 12 metabolites were significantly higher in the DSPN group compared with the other two groups. Additionally, they showed good performance to discriminate the DSPN state. Correlation analyses showed that the levels of 12 metabolites might be more closely related to the glucose metabolic changes, followed by the levels of lipid metabolism. CONCLUSIONS: The finding of the 12 signature metabolites might provide a novel perspective for the pathogenesis of DSPN. Future studies are required to test this observation further. John Wiley and Sons Inc. 2023-06-22 /pmc/articles/PMC10445193/ /pubmed/37347226 http://dx.doi.org/10.1111/jdi.14041 Text en © 2023 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Articles
Xu, Jiahui
Chen, Qingguang
Cai, Mengjie
Han, Xu
Lu, Hao
Ultra‐high performance liquid chromatography coupled to tandem mass spectrometry‐based metabolomics study of diabetic distal symmetric polyneuropathy
title Ultra‐high performance liquid chromatography coupled to tandem mass spectrometry‐based metabolomics study of diabetic distal symmetric polyneuropathy
title_full Ultra‐high performance liquid chromatography coupled to tandem mass spectrometry‐based metabolomics study of diabetic distal symmetric polyneuropathy
title_fullStr Ultra‐high performance liquid chromatography coupled to tandem mass spectrometry‐based metabolomics study of diabetic distal symmetric polyneuropathy
title_full_unstemmed Ultra‐high performance liquid chromatography coupled to tandem mass spectrometry‐based metabolomics study of diabetic distal symmetric polyneuropathy
title_short Ultra‐high performance liquid chromatography coupled to tandem mass spectrometry‐based metabolomics study of diabetic distal symmetric polyneuropathy
title_sort ultra‐high performance liquid chromatography coupled to tandem mass spectrometry‐based metabolomics study of diabetic distal symmetric polyneuropathy
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445193/
https://www.ncbi.nlm.nih.gov/pubmed/37347226
http://dx.doi.org/10.1111/jdi.14041
work_keys_str_mv AT xujiahui ultrahighperformanceliquidchromatographycoupledtotandemmassspectrometrybasedmetabolomicsstudyofdiabeticdistalsymmetricpolyneuropathy
AT chenqingguang ultrahighperformanceliquidchromatographycoupledtotandemmassspectrometrybasedmetabolomicsstudyofdiabeticdistalsymmetricpolyneuropathy
AT caimengjie ultrahighperformanceliquidchromatographycoupledtotandemmassspectrometrybasedmetabolomicsstudyofdiabeticdistalsymmetricpolyneuropathy
AT hanxu ultrahighperformanceliquidchromatographycoupledtotandemmassspectrometrybasedmetabolomicsstudyofdiabeticdistalsymmetricpolyneuropathy
AT luhao ultrahighperformanceliquidchromatographycoupledtotandemmassspectrometrybasedmetabolomicsstudyofdiabeticdistalsymmetricpolyneuropathy